 |
Dr. Thierry Boon Professor Extraordinaire Université Catholique de Louvain Director, Ludwig Institute for Cancer Research Brussels Branch Ave. Hippocrate 74 B U.C.L. 7459 1200 Brussels, Belgium |
Thierry Boon has observed that tumor cells that have acquired new mutations as a result of mutagen treatment in vitro, often become incapable of forming tumors because they express new antigens recognized by the T cells of the immune system. He was able to isolate the genes that code for these so-called tum- (tumor negative) antigens.
Thierry Boon was awarded for this work, which suggests that introducing tumor cell mutations might elicit an efficient therapeutic immune response in cancer patients.
 |
Dr. Ronald Levy Professor, School of Medicine Division of Oncology Stanford University Stanford, California 94305 U.S.A. |
Ronald Levy was the first to generate and to use monoclonal antibodies to treat patients with B cell lymphomas. Tumors which have grown back after initially responding to the antibody treatment were shown to express receptors slightly different from those in the primary tumor cells. He has done extensive work to define the basis of antitumor effects of the monoclonal antibodies and to analyze the limitations of the therapy. Ronald Levy received the prize for this hopeful new approach in cancer immunology.
| © The Webmaster of the Department of Physiology |
 |
Freitag, 16. Dezember 2005 |